Clinical Presentation & Protocol
Patient Usually Complains Of
Patient presents for evaluation of suspected anthracycline-induced cardiomyopathy (AIC). History significant for prior cumulative dose of [Doxorubicin/Daunorubicin] totaling [X] mg/m². Patient reports progressive dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea, and lower extremity edema. Symptoms correlate with recent chemotherapy cycles. No prior history of ischemic heart disease or valvular pathology.
Clinical Examination Findings
Cardiovascular exam reveals displaced apical impulse, S3 gallop, and holosystolic murmur at the apex consistent with functional mitral regurgitation. Jugular venous distension present at [X] cm above the sternal angle. Bilateral pitting edema (1+ to 3+) noted in lower extremities. Pulmonary exam demonstrates bibasilar crackles. Vital signs: Tachycardia noted, blood pressure [X/Y] mmHg.
Treatment Protocol
Initiate guideline-directed medical therapy (GDMT) for HFrEF, including ACE inhibitors/ARBs/ARNIs and beta-blockers (carvedilol/metoprolol succinate). Consider mineralocorticoid receptor antagonists (MRAs) and SGLT2 inhibitors. Discontinue or modify anthracycline regimen in consultation with oncology. Monitor LVEF via serial echocardiography or cardiac MRI. Implement strict sodium restriction (<2g/day) and fluid monitoring.